Manufacturer record
Sanofi India Limited: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Sanofi India Limited (Goa) were declared Not of Standard Quality between August 2019 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
2 records linked to Sanofi India Limited in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Glimepiride Tablets IP | 5GAC030Mfg 2025-12 · Exp 2028-11 | DissolutionDissolution | Lucknow LabState lab | Jul 2026 |
| Framycetin Skin Cream (Soframycin Skin Cream) | N8080Mfg 2018-04 · Exp 2020-09 | AssayAssay | CDL KolkataCDSCO lab | Aug 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.